Nanobio and Nanomedicine

Develops Nanobodies, antibody-derived therapeutic proteins that contain the unique structural and functional properties of naturally-occurring heavy-chain antibodies.

The company's nab™ drug delivery technology uses albumin nanoparticles to deliver drugs into tumors.

Serendip develops solutions and processes that combine advanced technology with environmental compatibility, providing high added value for manufacturers of creams, gels, lotions and ointments in the life sciences sector.

Accelr8 Technology Corporation is a developer of innovative materials and instrumentation for advanced applications in medical diagnostics, basic research, drug discovery, and bio-detection. Accelr8 is developing a new diagnostic platform, the BACcelr8r?, based on its proprietary surface coatings, assay processing, and detection technologies.

Access' lead anticancer program is ProLindac™ applies the principals of nanoparticulate prodrugs to enhance the delivery of a platinum drug to tumors.

Accium offers laboratory services based on its Accelerator Mass Spectrometry platform used to detect 14C/12C ratios which provided 1,000 times more sensitivity than the most sensitive method available today such as LC/MS. It is now possible to trace biomolecule delivery in healthy subjects with low attomole (10-18M) sensitivity.

Manufacturer of SilvaGard, a silver nanoparticle antimicrobial surface treatment for medical devices.

The basic technology platform of Activery™ is a nanoparticle production method using supercritical fluids (SCF). Based on SCF the company intends to create new medicines and modified active ingredients for pharmaceutical and cosmetic use.

The company has developed a proprietary formulation technology called HDDS that converts drugs that do not dissolve well in water, or hydrophobic drugs, into microparticles or nanoparticles of the drug embedded in small microspheres, such that the drug can more rapidly dissolve in water.

The company has developed and produced superparamagnetic nanoparticles for in vitro diagnostic and life sciences.

Develops enabling nucleic acid-based technology applications, aimed at large biosensor/molecular diagnostics, therapeutics, and energy generation/management markets.

The Advalytix chip-technology builds on nanopumps that need no moving parts to manipulate reagents measured by the billions of a liter for single cell assays.

Developer, manufacturer and distributor of innovative sample preparation devices for high sensitive mass spectrometry and liquid chromatography.

Digital microfluidics is a lab-on-a-chip approach based on direct, programmable micromanipulation of nanoliter volume droplets using electrical fields. Digital microfluidics enables complex, multi-step liquid handling protocols to be flexibly, scalably, and cost effectively implemented.

Advancell is active in nanomedicine. The company has two divisions: Pharma, which focuses its activity on the development of innovative drugs through the search for new applications for already-known molecules, and Services and Reagents, which uses cell-based in vitro methods to predict the efficacy, safety and mechanism of action of developing molecules.

Develops and to markets a novel, automated chip-based technology for mass spectrometry users with the microfluidics chip containing an array of nanoelectrospray nozzles.

Affymetrix GeneChip microarray technology is the industry-standard tool for analyzing complex genetic information. The GeneChip solution consists of oligonucleotide arrays, instruments to process and analyze the arrays, and software tools to manage and mine the data.

Agave BioSystems harnesses the extreme specificity and sensitivity of biological systems to build unique and useful nanoscale engineered devices and systems for diagnostic and analyical applications.

The company develops Rapid Early Detection products. These products identify possible pathological threats from bioterrorism to pathogens plaguing global agriculture, animals and people. Test arrays include nanoscale molecule detection techniques.

AION has focused on development of early stage diagnostics based on its nano-scale platform; modified porous silicon (mpSi).

A nano-biotechnology company with a nanoscale drug discovery technique for systematically scanning 'molecular diversity space'. The company has also developed technology for molecular manufacturing.

The company has developed Nanospider™, a unique patented technology enabling the production of nanofiber textiles for the wound care market on an industrial scale.

Alnis BioSciences has expertise in the fabrication of nanoparticles and the use of these particles for life science applications such as cancer treatment.

The company combines instruments, reagents and bioinformatics software to offer integrated modular technology platforms for functional genomics, proteomics and cell analysis markets.

AlphaSniffer LLC has developed a highly-sensitive biosensor for detection of trace amounts (pg/mm2) of bacteria, viruses, proteins, nucleic acids, antibodies and other biological and chemical agents in real-time. The unique patented biosensor design relies upon the common path interferometric detection principle in combination with the surface plasmon resonance effect.